T. Rowe Price Associates
KROS icon

T. Rowe Price Associates’s Keros Therapeutics KROS Stock Holding History

T. Rowe Price Associates’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$601K Buy
56,121
+10,245
+22% +$114K ﹤0.01% 2536
2026
Q1 		$507K Buy
45,876
+16,177
+54% +$250K ﹤0.01% 2453
2025
Q4 		$605K Sell
29,699
-20,282
-41% -$356K ﹤0.01% 2309
2025
Q3 		$791K Buy
49,981
+1,566
+3% +$23.1K ﹤0.01% 2164
2025
Q2 		$647K Buy
48,415
+5,188
+12% +$70K ﹤0.01% 2187
2025
Q1 		$441K Sell
43,227
-866,480
-95% -$10.1M ﹤0.01% 2299
2024
Q4 		$14.4M Sell
909,707
-604,798
-40% -$31.4M ﹤0.01% 1060
2024
Q3 		$87.9M Buy
1,514,505
+326,595
+27% +$16.1M 0.01% 595
2024
Q2 		$54.3M Sell
1,187,910
-30,594
-3% -$1.64M 0.01% 698
2024
Q1 		$80.7M Buy
1,218,504
+176,803
+17% +$10.5M 0.01% 595
2023
Q4 		$41.4M Sell
1,041,701
-225,531
-18% -$7.07M 0.01% 761
2023
Q3 		$40.4M Sell
1,267,232
-3,129
-0.2% -$117K 0.01% 747
2023
Q2 		$51M Buy
1,270,361
+117,845
+10% +$5.17M 0.01% 701
2023
Q1 		$49.2M Buy
1,152,516
+531,327
+86% +$26.8M 0.01% 689
2022
Q4 		$29.8M Buy
621,189
+611,459
+6,284% +$28.6M ﹤0.01% 810
2022
Q3 		$367K Buy
+9,730
New +$337K ﹤0.01% 2282
2022
Q2 		– Sell
-4,505
Closed -$245K – 2989
2022
Q1 		$245K Sell
4,505
-2,062
-31% -$106K ﹤0.01% 2636
2021
Q4 		$384K Buy
+6,567
New +$327K ﹤0.01% 2507

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

T. Rowe Price Associates's KROS Position: Q2 2026 in Review

T. Rowe Price Associates increased its Keros Therapeutics (KROS) stake by 22% in Q2 2026, buying an estimated $114K and bringing the position to 56,121 shares worth $601K. The position accounts for ﹤0.01% of the portfolio, ranked #2536.

T. Rowe Price Associates first reported a position in KROS in Q4 2021 and has held it in 18 quarters since. The position peaked at $87.9M in Q3 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • T. Rowe Price Associates held 56,121 shares of Keros Therapeutics worth $601K as of Q2 2026.
  • T. Rowe Price Associates bought 10,245 Keros Therapeutics shares in Q2 2026, an estimated $114K.
  • Keros Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2536 holding.
  • T. Rowe Price Associates first reported a position in Keros Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • T. Rowe Price Associates's Keros Therapeutics position peaked at $87.9M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.